Bellefleur has been acquired by Domidep
Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.
Headquartered in Aubange, Belgium, Bellefleur owns and operates a state-of-the-art nursing home in the Luxembourg province. After the nursing home’s refurbishment and extension in 2022, Bellefleur operates 91 accredited beds, with a total capacity for 99 beds. Through its strategic location, a limited competitive landscape in the region and efficient management, Bellefleur has been able to achieve an occupancy rate of around 100% for long-term stays since 2022.
Founded in 1989, Domidep is a leading player in the healthcare sector, operating mainly medicalized nursing homes. On the strength of its roots and experience in France, with almost 120 establishments at the end of 2022 accommodating 7,700 residents, Domidep is now also expanding internationally. The company is already present in Germany and Belgium, with over 35 establishments for almost 2,900 residents.
Oaklins’ team in Belgium acted as the exclusive M&A sell-side advisor to Bellefleur in this transaction.
Sprechen Sie mit dem Deal Team
Thomas Roelens
Oaklins KBC Securities
Transaktionen
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Mehr erfahrenbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Mehr erfahrenBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Mehr erfahren